🔬
Foundation Sciences · Genetics
Hereditary Cancer Syndromes (Lynch, BRCA)
Hereditary cancer syndromes are autosomal dominant conditions with high lifetime cancer risks, including BRCA1/2 and Lynch syndrome (mismatch repair gene mutations).
📌 Learning Objectives
- Describe the underlying mechanism of Hereditary Cancer Syndromes (Lynch, BRCA).
- Identify the key clinical features and complications of Hereditary Cancer Syndromes (Lynch, BRCA).
- Outline the appropriate investigations and management of Hereditary Cancer Syndromes (Lynch, BRCA).
- Discuss the implications for patients and families of Hereditary Cancer Syndromes (Lynch, BRCA).
📋 Overview
BRCA1/2 mutations confer high risks of breast and ovarian (and other) cancers. Lynch syndrome (MLH1, MSH2, MSH6, PMS2) causes colorectal, endometrial and other cancers from young ages.
🔬 Basic Science
BRCA1/2 mutations confer high risks of breast and ovarian (and other) cancers. Lynch syndrome (MLH1, MSH2, MSH6, PMS2) causes colorectal, endometrial and other cancers from young ages.
🏥 Clinical Relevance
Mainstreaming of BRCA testing in oncology services has expanded access.
🧪 Investigations
Investigation depends on clinical context: relevant blood tests, imaging, and specific genetic or histopathological tests as appropriate. Refer to specialist services where indicated.
💊 Management
Management is condition-specific and typically multidisciplinary, combining medical therapy, surgical intervention where appropriate, supportive care, and family/genetic counselling.
Revision Resources – expand the sections below for high-yield notes, exam pearls, key facts and further reading.
MLA High-Yield Notes & Quick Revision ⌄
Common SBA themes: recognising the underlying mechanism, identifying classic clinical features, and choosing the first-line investigation or management step. Watch for inheritance pattern and characteristic associations.
brca
lynch syndrome
mismatch repair
tumour suppressor
cancer genetics
- BRCA1/2 are autosomal dominant tumour suppressor genes.
- BRCA1 carriers: ~70% lifetime breast cancer risk, ~40% ovarian.
- Lynch syndrome is due to mismatch repair gene mutations (MLH1, MSH2, MSH6, PMS2).
- Lynch syndrome predisposes to colorectal, endometrial, ovarian and other cancers.
- Genetic testing follows established UK clinical criteria and counselling pathways.
Exam Pearls ⌄
⭐ High Yield
BRCA1/2 are autosomal dominant tumour suppressor genes.
BRCA1 carriers: ~70% lifetime breast cancer risk, ~40% ovarian.
Lynch syndrome is due to mismatch repair gene mutations (MLH1, MSH2, MSH6, PMS2).
Lynch syndrome predisposes to colorectal, endometrial, ovarian and other cancers.
Genetic testing follows established UK clinical criteria and counselling pathways.
💡 Clinical Pearl
Brca: Mainstreaming of BRCA testing in oncology services has expanded access.
⚠️ Exam Tip — Common Mistakes
Confusing the mechanism of Hereditary Cancer Syndromes (Lynch, BRCA) with related conditions.
Missing classic clinical features of Hereditary Cancer Syndromes (Lynch, BRCA) in SBA stems.
Failing to consider Hereditary Cancer Syndromes (Lynch, BRCA) in the differential diagnosis.
Key Facts ⌄
BRCA1/2 are autosomal dominant tumour suppressor genes.
BRCA1 carriers: ~70% lifetime breast cancer risk, ~40% ovarian.
Lynch syndrome is due to mismatch repair gene mutations (MLH1, MSH2, MSH6, PMS2).
Lynch syndrome predisposes to colorectal, endometrial, ovarian and other cancers.
Genetic testing follows established UK clinical criteria and counselling pathways.
Related Topics ⌄
References ⌄
- GMC MLA Content Map
- NICE Clinical Knowledge Summaries
- BMJ Best Practice
Further Resources
Medical Portfolio & Career Development
Build a professional portfolio website for applications, audits, teaching, research and career progression.
CVtoWebsite.com →